Novel approaches to acute graft-versus-host disease prevention

3.

Fuchs

EJ

,

O'Donnell

PV

,

Eapen

M

, et al.

Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial

.

Blood

.

2021

;

137

(

3

):

420

-

428

.

doi:10.1182/blood.2020007535

.

4.

Gooptu

M

,

Romee

R

,

St Martin

A

, et al.

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

.

Blood

.

2021

;

138

(

3

):

273

-

282

.

doi:10.1182/blood.2021011281

.

5.

Duléry

R

,

Bastos

J

,

Paviglianiti

A

, et al.

Thiotepa, busulfan, and fludarabine conditioning regimen in T cell-replete HLA-haploidentical hematopoietic stem cell transplantation

.

Biol Blood Marrow Transplant

.

2019

;

25

(

7

):

1407

-

1415

.

doi:10.1016/j.bbmt.2019.02.025

.

6.

Hong

KT

,

Kang

HJ

,

Choi

JY

, et al.

Favorable outcome of post-transplantation cyclophosphamide haploidentical peripheral blood stem cell transplantation with targeted busulfan-based myeloablative conditioning using intensive pharmacokinetic monitoring in pediatric patients

.

Biol Blood Marrow Transplant

.

2018

;

24

(

11

):

2239

-

2244

.

doi:10.1016/j.bbmt.2018.06.034

.

7.

Symons

HJ

,

Zahurak

M

,

Cao

Y

, et al.

Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults

.

Blood Adv

.

2020

;

4

(

16

):

3913

-

3925

.

doi:10.1182/bloodadvances.2020001648

.

8.

Fierro-Pineda

JC

,

Tsai

H-L

,

Blackford

AL

, et al.

Prospective PTCTC trial of myeloablative haploBMT with post-transplant cyclophosphamide for pediatric acute leukemias [published online May 23, 2023]

.

Blood Adv

.

doi:10.1182/bloodadvances.2023010281

.

9.

Bolaños-Meade

J

,

Reshef

R

,

Fraser

R

, et al.

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

.

Lancet Haematol

.

2019

;

6

(

3

):

e132

-

e143

.

doi:10.1016/S2352-3026(18)30221-7

.

10.

Bolaños-Meade

J

,

Hamadani

M

,

Wu

J

, et al;

BMT CTN 1703 Investigators

.

Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis

.

N Engl J Med

.

2023

;

388

(

25

):

2338

-

2348

.

doi:10.1056/NEJMoa2215943

.

11.

Zhao

C

,

Bartock

M

,

Jia

B

, et al.

Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant

.

J Hematol Oncol

.

2022

;

15

(

1

):

64

.

doi:10.1186/s13045-022-01287-3

.

12.

Goldsmith

SR

,

Abid

MB

,

Auletta

JJ

, et al.

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

.

Blood

.

2021

;

137

(

23

):

3291

-

3305

.

doi:10.1182/blood.2020009362

.

13.

Luznik

L

,

Pasquini

MC

,

Logan

B

, et al.

Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies

.

J Clin Oncol

.

2022

;

40

(

4

):

356

-

368

.

doi:10.1200/JCO.21.02293

.

14.

Jurdi

NE

,

Hoover

A

,

O'Leary

D

, et al.

Phase II study of myeloablative 7-8/8-matched allotransplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil [published online June 11, 2023]

.

Transplant Cell Ther

.

doi:10.1016/j.jtct.2023.06.008

.

15.

Shaw

BE

,

Jimenez-Jimenez

AM

,

Burns

LJ

, et al.

National marrow donor program-Sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide

.

J Clin Oncol

.

2021

;

39

(

18

):

1971

-

1982

.

doi:10.1200/JCO.20.03502

.

16.

Watkins

B

,

Qayed

M

,

McCracken

C

, et al.

Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD

.

J Clin Oncol

.

2021

;

39

(

17

):

1865

-

1877

.

doi:10.1200/JCO.20.01086

.

17.

Kean

LS

,

Burns

LJ

,

Kou

TD

, et al.

A real-world evidence comparison of 1-year overall survival and relapse-free survival between patients treated with abatacept in combination with a calcineurin inhibitor and methotrexate versus antithymocyte globulin or post-transplant cyclophosphamide following allogeneic hematopoietic cell transplantation

.

Blood

.

2022

;

140

(

suppl 1

):

1373

-

1375

.

doi:10.1182/blood-2022-157610

.

18.

Raghunandan

S

,

Gorfinkel

L

,

Graiser

M

, et al.

Abatacept for the prevention of GVHD in patients receiving mismatched unrelated transplants: a real-world analysis

.

Blood Adv

.

2023

;

7

(

16

):

4395

-

4399

.

doi:10.1182/bloodadvances.2023010225

.

19.

Qayed

M

,

Watkins

B

,

Gillespie

S

, et al.

Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation

.

Blood Adv

.

2022

;

6

(

3

):

746

-

749

.

doi:10.1182/bloodadvances.2021005208

.

20.

Stenger

EO

,

Watkins

B

,

Rogowski

K

, et al.

Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure

.

Blood Adv

.

2023

;

7

(

10

):

2196

-

2205

.

doi:10.1182/bloodadvances.2022008545

.

21.

Ngwube

A

,

Shah

N

,

Godder

K

,

Jacobsohn

D

,

Hulbert

ML

,

Shenoy

S.

Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease

.

Blood Adv

.

2020

;

4

(

16

):

3894

-

3899

.

doi:10.1182/bloodadvances.2020002236

.

22.

Leahy

AB

,

Li

Y

,

Talano

J-A

, et al.

Unrelated donor α/β T cell- and B cell-depleted HSCT for the treatment of pediatric acute leukemia

.

Blood Adv

.

2022

;

6

(

4

):

1175

-

1185

.

doi:10.1182/bloodadvances.2021005492

.

23.

Sisinni

L

,

Gasior

M

,

de Paz

R

, et al.

Unexpected high incidence of human herpesvirus-6 encephalitis after naive T cell–depleted graft of haploidentical stem cell transplantation in pediatric patients

.

Biol Blood Marrow Transplant

.

2018

;

24

(

11

):

2316

-

2323

.

doi:10.1016/j.bbmt.2018.07.016

.

24.

Bethge

WA

,

Eyrich

M

,

Mielke

S

, et al.

Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients

.

Bone Marrow Transplant

.

2022

;

57

(

3

):

423

-

430

.

doi:10.1038/s41409-021-01551-z

.

25.

Bleakley

M

,

Sehgal

A

,

Seropian

S

, et al.

Naive T-cell depletion to prevent chronic graft-versus-host disease

.

J Clin Oncol

.

2022

;

40

(

11

):

1174

-

1185

.

doi:10.1200/jco.21.01755

.

26.

Schumm

M

,

Lang

P

,

Handgretinger

R.

Graft manipulation

. In:

E

Carreras

,

C

Dufour

,

M

Mohty

, (eds).

The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies

.

Springer

;

2019

.

27.

Diaz

MA

,

Zubicaray

J

,

Molina

B

, et al.

Haploidentical stem cell transplantation in children with hematological malignancies using αβ+ T-cell receptor and CD19+ cell depleted grafts: high CD56dim/CD56bright NK cell ratio early following transplantation is associated with lower relapse incidence and better outcome

.

Front Immunol

.

2019

;

10

:

2504

.

doi:10.3389/fimmu.2019.02504

.

28.

de Witte

MA

,

Janssen

A

,

Nijssen

K

, et al.

αβ T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies

.

Blood Adv

.

2021

;

5

(

1

):

240

-

249

.

doi:10.1182/bloodadvances.2020002444

.

29.

Bertaina

A

,

Zecca

M

,

Buldini

B

, et al.

Unrelated donor vs HLA-haploidentical α/β T-cell- and B-cell-depleted HSCT in children with acute leukemia

.

Blood

.

2018

;

132

(

24

):

2594

-

2607

.

doi:10.1182/blood-2018-07-861575

.

30.

Meyer

EH

,

Laport

G

,

Xie

BJ

, et al.

Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients

.

JCI Insight

.

2019

;

4

(

10

).

doi:10.1172/jci.insight.127244

.

31.

Oliai

C

,

Hoeg

RT

,

Pavlova

A

, et al.

Precision-engineered cell therapy orca-T demonstrates high relapse-free survival at 1 year while reducing graft- versus-host disease and toxicity

.

Blood

.

2022

;

140

(

suppl 1

):

654

-

656

.

doi:10.1182/blood-2022-165654

.

32.

Baron

F

,

Mohty

M

,

Blaise

D

, et al.

Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

.

Haematologica

.

2017

;

102

(

2

):

224

-

234

.

doi:10.3324/haematol.2016.148510

.

33.

Walker

I

,

Panzarella

T

,

Couban

S

, et al.

Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial

.

Lancet Oncol

.

2016

;

17

(

2

):

164

-

173

.

doi:10.1016/s1470-2045(15)00462-3

.

34.

Nagler

A

,

Kanate

AS

,

Labopin

M

, et al.

Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia

.

Haematologica

.

2021

;

106

(

6

):

1591

-

1598

.

doi:10.3324/haematol.2020.247296

.

35.

Finazzi

MC

,

Boschini

C

,

Craddock

C

,

Rambaldi

A

,

Ward

J

,

Malladi

RK

.

Characteristics of graft-versus-host disease occurring after alemtuzumab- containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival

.

Br J Haematol

.

2020

;

188

(

4

):

550

-

559

.

doi:10.1111/bjh.16200

.

36.

Farag

SS

,

Abu Zaid

M

,

Schwartz

JE

, et al.

Dipeptidyl peptidase 4 inhibition for prophylaxis of acute graft-versus-host disease

.

N Engl J Med

.

2021

;

384

(

1

):

11

-

19

.

doi:10.1056/NEJMoa2027372

.

37.

DeFilipp

Z

,

Kim

HT

,

Knight

L

, et al.

Prolonged post-transplant ruxolitinib therapy is associated with protection from severe GVHD after allogeneic HCT

.

Transplant Cell Ther

.

2022

;

28

(

3

):

S305

-

S306

.

doi:10.1016/s2666-6367(22)00553-x

.

38.

Choi

SW

,

Braun

T

,

Henig

I

, et al.

Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT

.

Blood

.

2017

;

130

(

15

):

1760

-

1767

.

doi:10.1182/blood-2017-06-790469

.

39.

del Pozo Martín

Y.

49th annual meeting of the EBMT

.

Lancet Haematol

.

2023

;

10

(

6

):

e400

-

e401

.

doi:10.1016/s2352-3026(23)00121-7

.

40.

Al-Homsi

AS

,

Cirrone

F

,

Wo

S

, et al.

PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation

.

Blood Adv

.

2023

;

7

(

14

):

3604

-

3611

.

doi:10.1182/bloodadvances.2023010545

.

41.

Salas

MQ

,

Prem

S

,

Atenafu

EG

, et al.

Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD

.

Bone Marrow Transpl

.

2020

;

55

(

9

):

1773

-

1783

.

doi:10.1038/s41409-020-0813-9

.

42.

DeZern

AE

,

Zahurak

M

,

Symons

HJ

, et al.

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

.

Blood

.

2023

;

141

(

25

):

3031

-

3038

.

doi:10.1182/blood.2023020435

.